N-[[6-(Hydroxyamino)-6-oxohexyl]oxy]-3,5-dimethylbenzamide LMK-235
LMK 235
CAS: 1418033-25-6
Molecular Formula: C15H22N2O4
N-[[6-(Hydroxyamino)-6-oxohexyl]oxy]-3,5-dimethylbenzamide LMK-235 - Names and Identifiers
| Name | LMK 235 |
| Synonyms | LMK235 CS-1820 LMK 235 LMK-235 LMK 235 LMK-235 (Fandachem) N-[[6-(Hydroxyamino)-6-oxohexyl]oxy]-3,5-dimethyl-benzamide Benzamide, N-[[6-(hydroxyamino)-6-oxohexyl]oxy]-3,5-dimethyl- N-[[6-(Hydroxyamino)-6-oxohexyl]oxy]-3,5-dimethylbenzamide LMK-235 |
| CAS | 1418033-25-6 |
| EINECS | 808-770-7 |
| InChIKey | VRYZCEONIWEUAV-UHFFFAOYSA-N |
N-[[6-(Hydroxyamino)-6-oxohexyl]oxy]-3,5-dimethylbenzamide LMK-235 - Physico-chemical Properties
| Molecular Formula | C15H22N2O4 |
| Molar Mass | 294.35 |
| Density | 1.155±0.06 g/cm3(Predicted) |
| Melting Point | 135-138°C |
| Solubility | Soluble in DMSO |
| Appearance | powder |
| Color | white to beige |
| pKa | 9.46±0.20(Predicted) |
| Storage Condition | 2-8°C |
| Use | LMK-235 is a selective histone deacetylase (HDAC) 4 and HDAC5 inhibitor. LMK-235 demonstrates activity against chemoresistant cancer cell lines in an MTT assay for cytotoxicity using human ovarian cancer cell lines A2780 and cisplatin resistant A2780CisR (IC50 = 0.49 and 0.32 μ M respectively). |
| Target | HDAC4; HDAC5; |
N-[[6-(Hydroxyamino)-6-oxohexyl]oxy]-3,5-dimethylbenzamide LMK-235 - Risk and Safety
| Hazard Symbols | Xn - Harmful |
| Risk Codes | 22 - Harmful if swallowed |
| WGK Germany | 3 |
N-[[6-(Hydroxyamino)-6-oxohexyl]oxy]-3,5-dimethylbenzamide LMK-235 - Reference
| Reference Show more | 1: Hansen FK, Sumanadasa SD, Stenzel K, Duffy S, Meister S, Marek L, Schmetter R, Kuna K, Hamacher A, Mordmüller B, Kassack MU, Winzeler EA, Avery VM, Andrews KT, Kurz T. Discovery of HDAC inhibitors with potent activity against multiple malaria parasite life cycle stages. Eur J Med Chem. 2014 Jul 23;82:204-13. doi: 10.1016/j.ejmech.2014.05.050. Epub 2014 May 22. PubMed PMID: 24904967. 2: Marek L, Hamacher A, Hansen FK, Kuna K, Gohlke H, Kassack MU, Kurz T. Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells. J Med Chem. 2013 Jan 24;56(2):427-36. doi: 10.1021/jm301254q. Epub 2013 Jan 8. PubMed PMID: 23252603. |
N-[[6-(Hydroxyamino)-6-oxohexyl]oxy]-3,5-dimethylbenzamide LMK-235 - Preparation solution concentration reference
| 1mg | 5mg | 10mg | |
|---|---|---|---|
| 1 mM | 3.397 ml | 16.987 ml | 33.973 ml |
| 5 mM | 0.679 ml | 3.397 ml | 6.795 ml |
| 10 mM | 0.34 ml | 1.699 ml | 3.397 ml |
| 5 mM | 0.068 ml | 0.34 ml | 0.679 ml |
Last Update：2024-01-02 23:10:35
N-[[6-(Hydroxyamino)-6-oxohexyl]oxy]-3,5-dimethylbenzamide LMK-235 - Cell Experiment
The rate of cell survival under the action of test substances is evaluated by an improved MTT assay. The assay is based on the ability of viable cells to metabolize yellow MTT to violet formazan that can be detected spectrophotometrically. In brief, A2780, Cal27, Kyse510, and MDA-MB-231 cell lines are seeded at a density of 5000, 7000, 8000, and 10 000 cells/well in 96-well plates. After 24 h, cells are exposed to increased concentrations of the test compounds. Incubation is ended after 72 h, and cell survival is determined by addition of MTT solution (5 mg/mL in phosphate buffered saline). The formazan precipitate is dissolved in DMSO. Absorbance s measured at 544 and 690 nm in a FLUOstar microplate reader. (Only for Reference)
Last Update：2023-08-16 21:32:38
![N-[[6-(Hydroxyamino)-6-oxohexyl]oxy]-3,5-dimethylbenzamide LMK-235](http://res.chembk.com/assets/images/structure/519677.gif)
Supplier List
Spot supply
Product Name: LMK 235 Visit Supplier Webpage Request for quotationCAS: 1418033-25-6
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Spot supply
Product Name: LMK 235 Visit Supplier Webpage Request for quotationCAS: 1418033-25-6
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History